Abstract
Bacterial biofilms are estimated to be associated with over 65 percent of all nosocomial infections. However, no therapeutics have been approved by the FDA which directly mediate biofilm formation or persistence. Herein we report oxazine as a highly potent inhibitor, disperser and in the presence of the appropriate antibiotic eradicator of V. cholerae biofilms.
Highlights
Bacterial biofilms are estimated to be associated with over 65 percent of all nosocomial infections
No therapeutics have been approved by the FDA which directly mediate biofilm formation or persistence
Unlike cells in the planktonic state, bacterial biofilms do not exert their antimicrobial resistance through mutation or acquisition of resistance functions by horizontal gene transfer.[3]
Summary
Bacterial biofilms are estimated to be associated with over 65 percent of all nosocomial infections. A limited number of small molecule inhibitors of V. cholerae biofilms have been reported in the literature, both from natural product screening campaigns and medicinal chemistry development efforts.[6,7] in the majority of cases these compounds have been shown to impact quorum sensing (QS) rather than directly targeting processes involved with biofilm matrix production or regulation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
